吕军强 - 天津医科大学

个人简介

教育背景 2008/09-2011/07 天津医科大学医学免疫学医学博士学位 2005/09-2008/07 天津医科大学临床检验诊断学医学硕士学位 2000/09-2005/07 天津医科大学医学检验学医学学士学位工作经历 2016/02-至今天津医科大学 2008/08-2015/11 深圳康哲医药发展有限公司

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Zhao X, Wang X, Li Q, Chen W, Zhang N, Kong Y, Lv J, Cao L, Lin D, Wang X, Xu G, Wu X*. FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway. Cell Death Dis. 2018, 19; 9(2):46. 2.Guo Y, Zhang Z, Wei H, Wang J, Lv J, Zhang K, Keller ET, Yao Z*, Wang Q*. Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis. J Pathol, 2017, 243(2):208-219. 3.Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, Yao Z. Effects of Tyroserleutide on phosphatidylinositol 3'-kinase/AKT pathway in human hepatocellular carcinoma cell. J Drug Target, 2013, 22(2):146-55 4.Xu Q, Lu R, Zhu ZF, Lv JQ, Wang LJ, Zhang W, Hu JW, Meng J, Lin G, Yao Z*. Effects of tyroservatide on histone acetylation in lung carcinoma cells. Int J Cancer, 2011, 128(2):460-72. 5.Lv JQ#, Zhang W, Wang S, Zhao L, Ma R, Hu JW, Wang LJ, Meng J, Zhou CL, Lin G, Lu R, Yao Z*. The pentapeptide PLNPK inhibits systemic lupus erythematosus-associated renal damage. Inflamm Res, 2010, 59(12):1081-9. 6.Wang C, Wang S, Lu R, Zhao L, Zhu ZF, Xu Q, Lv JQ, Wang LL, Fu Z, Lin G, Yao Z*. Effects of a novel tripeptide, tyroserleutide (YSL), on cell cycle progression of human hepatocellular carcinoma. Anticancer Drugs. 2009, 20(7):534-42. 7.Zhou CL#, Lv JQ#, Lu R, Chen LJ, Li HQ, Cao HL, Li QL, Wang S, Fu Z, Yao Z*. A new pentapeptide compound, PLNPK, ameliorates anti-glomerular basement membrane nephritis in Wistar rats. Peptides, 2008, 29(10):1789-97. （co-first author）